ABSTRACT
Although autoimmune myasthenia gravis (MG) is a relatively uncommon clinical disorder, it is one of the most extensively studied and best understood autoimmune diseases. Advances in our understanding of the pathophysiology and the immunopathogenesis of MG have allowed for the development of increasingly selective and targeted therapeutic interventions. The prognosis of the disease has been dramatically altered over the last 50 years, from a disorder that was marginally treatable and often fatal to one in which treatment is very successful in the majority of cases.
